A retrospective analysis of 738 adults with Ph+ALL who underwent allogeneic hematopoietic cell transplantation (HCT) found that pre-transplant imatinib had beneficial effects on overall survival, relapse, and non-relapse mortality compared to a non-imatinib cohort of HCT recipients. Patients between the ages of 16-59 received HCT between 1990 and 2010 and were reported to the Japan Transplant Registry. Five-year overall survival was significantly higher in the imatinib cohort than in the non-imatinib cohort: 59% vs. 38%, respectively; (p<0.001).
Mizuta S, et al. BloodPre-Transplant Imatinib Benefits Adults with Ph+ ALL
Mar 2014